US equities
|
MU
$877.55
▲+2.46%
NVDA
$210.96
▼-0.59%
SPCX
$147.49
▲+1.89%
AAPL
$347.73
▼-0.14%
TSLA
$372.22
▼-0.63%
SNDK
$1,238.03
▼-1.82%
META
$642.62
▼-0.96%
AMD
$516.79
▲+1.74%
MU
$877.55
▲+2.46%
NVDA
$210.96
▼-0.59%
SPCX
$147.49
▲+1.89%
AAPL
$347.73
▼-0.14%
TSLA
$372.22
▼-0.63%
SNDK
$1,238.03
▼-1.82%
META
$642.62
▼-0.96%
AMD
$516.79
▲+1.74%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Articles published by Enlivex Ltd.
Enlivex Announces 1-for-16 Reverse Share Split to be Effective October 27, 2026
October 22, 2026
From
Enlivex Ltd.
Via
GlobeNewswire
Tickers
ENLV
Enlivex Announces Cost Reduction Plan to Focus Resources on Phase 2b Trial of Allocetra™ in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis
October 19, 2026
From
Enlivex Ltd.
Via
GlobeNewswire
Tickers
ENLV
Enlivex Announces Termination of Previously-Announced Financing Payable in RAIN Tokens
September 22, 2026
From
Enlivex Ltd.
Via
GlobeNewswire
Tickers
ENLV
Enlivex Treasury Portfolio Update: RAIN Trading Volume Reaches $860MM, 622% Month-Over-Month Growth in July vs June
July 30, 2026
From
Enlivex Ltd.
Via
GlobeNewswire
Tickers
ENLV
Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones
July 29, 2026
From
Enlivex Ltd.
Via
GlobeNewswire
Tickers
ENLV
Enlivex Announces $400,000,000 Private Placement
July 28, 2026
From
Enlivex Ltd.
Via
GlobeNewswire
Tickers
ENLV
Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion
July 20, 2026
From
Enlivex Ltd.
Via
GlobeNewswire
Tickers
ENLV
Enlivex Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Allocetra™ in Age-Related Knee Osteoarthritis
July 13, 2026
From
Enlivex Ltd.
Via
GlobeNewswire
Tickers
ENLV
Enlivex Announces 1-for-15 Reverse Stock Split Effective July 9, 2026
July 07, 2026
From
Enlivex Ltd.
Via
GlobeNewswire
Tickers
ENLV
Enlivex Treasury Portfolio Update: Listing of the RAIN Token on Gate, One of the World's Largest Cryptocurrency Exchanges by Spot Trading Volume
June 24, 2026
From
Enlivex Ltd.
Via
GlobeNewswire
Tickers
ENLV
Enlivex Treasury Portfolio Update: RAIN Holdings Valued at Approximately $1.14 Billion
June 22, 2026
From
Enlivex Ltd.
Via
GlobeNewswire
Tickers
ENLV
Enlivex Announces Issuance of Australian Patent Covering the Use of Allocetra™ in Patients with Osteoarthritis
June 15, 2026
From
Enlivex Ltd.
Via
GlobeNewswire
Tickers
ENLV
ENLIVEX TO PRESENT QUALITY LONGEVITY MODEL POWERED BY PREDICTION MARKETS TREASURY AT PROOF OF TALK 2026
June 02, 2026
From
Enlivex Ltd.
Via
GlobeNewswire
Tickers
ENLV
Allocetra Shows Durable 6-Month Efficacy in Knee Osteoarthritis Phase IIa Trial; Oral Presentation at EULAR 2026
June 01, 2026
From
Enlivex Ltd.
Via
GlobeNewswire
Tickers
ENLV
Enlivex Treasury Portfolio Update: RAIN Holdings Valued at Approximately $1.16 Billion; Rain Foundation Appoints Industry Leaders to Advisory Board
May 28, 2026
From
Enlivex Ltd.
Via
GlobeNewswire
Tickers
ENLV
Enlivex Treasury Portfolio Update: Rain Protocol Jumps Into Top Three Global Prediction Markets In League Table Following $100M In Additional Liquidity
May 27, 2026
From
Enlivex Ltd.
Via
GlobeNewswire
Tickers
ENLV
Enlivex Announces Dosing Of First Patient In The United States As Part Of Its Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis
May 18, 2026
From
Enlivex Ltd.
Via
GlobeNewswire
Tickers
ENLV
Enlivex Announces Receipt of Nasdaq Minimum Bid Price Notification
May 15, 2026
From
Enlivex Ltd.
Via
GlobeNewswire
Tickers
ENLV
Enlivex Treasury Portfolio Update: Listing of the RAIN Token on HTX, a Leading Cryptocurrency Exchange
April 30, 2026
From
Enlivex Ltd.
Via
GlobeNewswire
Tickers
ENLV
Enlivex Treasury Update: Total RAIN Holdings Rise to 78,819,756,062 Tokens as of April 27, 2026, Representing an Aggregated Value of $567 Million
April 28, 2026
From
Enlivex Ltd.
Via
GlobeNewswire
Tickers
ENLV
Enlivex to Present Phase IIa 3-month and 6-month Data of Allocetra at OARSI 2026 World Congress
April 23, 2026
From
Enlivex Ltd.
Via
GlobeNewswire
Tickers
ENLV
Enlivex Announces Second Regulatory Approval for Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis
April 21, 2026
From
Enlivex Ltd.
Via
GlobeNewswire
Tickers
ENLV
Enlivex Rain Update: Rain Launches an OpenClaw and AI Agent Interface Allowing Anyone To Create A Prediction Market Via A Single Prompt
March 26, 2026
From
Enlivex Ltd.
Via
GlobeNewswire
Tickers
ENLV
Enlivex Reports Full-Year 2025 Results: Profit (Net Income) of $1.23 Billion and Diluted Earnings Per Share (EPS) of $25.48
March 25, 2026
From
Enlivex Ltd.
Via
GlobeNewswire
Tickers
ENLV
Enlivex Announces $21 Million Debt Financing, Decentralized Prediction Markets RAIN Token-Related Updates and $20 Million Share Repurchase Program
March 24, 2026
From
Enlivex Ltd.
Via
GlobeNewswire
Tickers
ENLV
Quality Longevity Company Enlivex Receives Investigational New Drug (IND) Clearance from the FDA for Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis
March 23, 2026
From
Enlivex Ltd.
Via
GlobeNewswire
Tickers
ENLV
